Charles River Laboratories International CRL announced today
that it has acquired Accugenix, Inc., the premier global provider of
cGMP-compliant contract microbial identification testing, for approximately
$17 million in cash. This acquisition strengthens Charles River's Endotoxin
and Microbial Detection^1 (EMD) portfolio of products and services by
providing clients with state-of-the-art microbial detection services for
manufacturing in the biopharmaceutical, medical device, nutraceutical and
consumer care industries. The acquisition is expected to be neutral to
earnings per share on both a GAAP and non-GAAP basis in 2012. In 2013, it is
expected to represent approximately 1% of total net sales and be slightly
accretive to both GAAP and non-GAAP earnings per share.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in